Back to Search
Start Over
[ALK inhibitor].
- Source :
-
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2011 Jan; Vol. 38 (1), pp. 27-30. - Publication Year :
- 2011
-
Abstract
- While lung cancer is the leading cause of cancer deaths worldwide, the molecular mechanism underlying its carcinogenesis is mainly unknown. We have discovered a small, fusion-type tyrosine kinase EML4-ALK that is generated through a tiny inversion within the short arm of human chromosome 2. Transgenic mice expressing EML4-ALK in lung developed hundreds of lung cancer nodules soon after birth, but such nodules were readily eradicated upon treatment with an ALK inhibitor. Clinical trials for EML4-ALK-positive lung cancer with an ALK inhibitor is ongoing, with its interim results being highly promising.
- Subjects :
- Anaplastic Lymphoma Kinase
Animals
Humans
Lung Neoplasms enzymology
Lung Neoplasms genetics
Molecular Targeted Therapy
Oncogene Proteins, Fusion genetics
Oncogene Proteins, Fusion metabolism
Protein-Tyrosine Kinases genetics
Protein-Tyrosine Kinases metabolism
Receptor Protein-Tyrosine Kinases
Lung Neoplasms drug therapy
Protein Kinase Inhibitors therapeutic use
Protein-Tyrosine Kinases antagonists & inhibitors
Subjects
Details
- Language :
- Japanese
- ISSN :
- 0385-0684
- Volume :
- 38
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Gan to kagaku ryoho. Cancer & chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 21368458